These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27212476)

  • 1. A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.
    Adam F; Casari C; Prévost N; Kauskot A; Loubière C; Legendre P; Repérant C; Baruch D; Rosa JP; Bryckaert M; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Sci Rep; 2016 May; 6():26306. PubMed ID: 27212476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
    Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
    Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.
    Casari C; Berrou E; Lebret M; Adam F; Kauskot A; Bobe R; Desconclois C; Fressinaud E; Christophe OD; Lenting PJ; Rosa JP; Denis CV; Bryckaert M
    J Clin Invest; 2013 Dec; 123(12):5071-81. PubMed ID: 24270421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.
    Golder M; Pruss CM; Hegadorn C; Mewburn J; Laverty K; Sponagle K; Lillicrap D
    Blood; 2010 Jun; 115(23):4862-9. PubMed ID: 20371742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.
    Rayes J; Hollestelle MJ; Legendre P; Marx I; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Blood; 2010 Jun; 115(23):4870-7. PubMed ID: 20200350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
    Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
    Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.
    Tischer A; Brehm MA; Machha VR; Moon-Tasson L; Benson LM; Nelton KJ; Leger RR; Obser T; Martinez-Vargas M; Whitten ST; Chen D; Pruthi RK; Bergen HR; Cruz MA; Schneppenheim R; Auton M
    J Mol Biol; 2020 Jan; 432(2):305-323. PubMed ID: 31628947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.
    Dupont A; Soukaseum C; Cheptou M; Adam F; Nipoti T; Lourenco-Rodrigues MD; Legendre P; Proulle V; Rauch A; Kawecki C; Bryckaert M; Rosa JP; Paris C; Ternisien C; Boisseau P; Goudemand J; Borgel D; Lasne D; Maurice P; Lenting PJ; Denis CV; Susen S; Kauskot A
    Haematologica; 2019 Dec; 104(12):2493-2500. PubMed ID: 30819911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality.
    Castaman G; Federici AB
    Semin Thromb Hemost; 2016 Jul; 42(5):478-82. PubMed ID: 27148840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.
    Casonato A; Gallinaro L; Cattini MG; Pontara E; Padrini R; Bertomoro A; Daidone V; Pagnan A
    Haematologica; 2010 Aug; 95(8):1366-72. PubMed ID: 20305138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.
    Kauskot A; Poirault-Chassac S; Adam F; Muczynski V; Aymé G; Casari C; Bordet JC; Soukaseum C; Rothschild C; Proulle V; Pietrzyk-Nivau A; Berrou E; Christophe OD; Rosa JP; Lenting PJ; Bryckaert M; Denis CV; Baruch D
    JCI Insight; 2016 Oct; 1(16):e88643. PubMed ID: 27734030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.
    Slobodianuk TL; Kochelek C; Foeckler J; Kalloway S; Weiler H; Flood VH
    J Thromb Haemost; 2019 Jan; 17(1):63-71. PubMed ID: 30565388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
    Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
    Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia.
    Casari C; Du V; Wu YP; Kauskot A; de Groot PG; Christophe OD; Denis CV; de Laat B; Lenting PJ
    Blood; 2013 Oct; 122(16):2893-902. PubMed ID: 23945153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.
    Berrou E; Kauskot A; Adam F; Harel A; Legendre P; Lavenu Bombled C; Rothschild C; Prevost N; Christophe OD; Lenting PJ; Denis CV; Rosa JP; Bryckaert M
    PLoS One; 2015; 10(12):e0143896. PubMed ID: 26645283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain.
    Legan ER; Liu Y; Arce NA; Parker ET; Lollar P; Zhang XF; Li R
    Blood; 2023 Mar; 141(10):1221-1232. PubMed ID: 36580664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shear stress-independent binding of von Willebrand factor-type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance.
    Wohner N; Legendre P; Casari C; Christophe OD; Lenting PJ; Denis CV
    J Thromb Haemost; 2015 May; 13(5):815-20. PubMed ID: 25728415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.